Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease

Blood

Volumn 107, Issue 9, 2006, Pages 3753-3760

  Mintz, Paul D ^a   Bass, Nathan M ^b   Petz, Lawrence D ^b   Steadman, Randolph ^b   Streiff, Michael ^b   McCullough, Jeffery ^b   Burks, Sandra ^b   Wages, David ^b   Van Doren, Sally ^b   Corash, Laurence ^b  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 7; CARDIOLIPIN ANTIBODY; FRESH FROZEN PLASMA; PROTEIN C; PROTEIN S;

ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; BLOOD CLOTTING DISORDER; BLOOD COMPONENT; BLOOD DISEASE; BLOOD TRANSFUSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EYE DISEASE; FEMALE; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HEMOSTASIS; HEPATOBILIARY DISEASE; HUMAN; IMMUNOPATHOLOGY; INJECTION SITE REACTION; INJURY; INTOXICATION; KIDNEY DISEASE; LIVER DISEASE; LIVER TRANSPLANTATION; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METABOLIC DISORDER; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; PARTIAL THROMBOPLASTIN TIME; PHOTOCHEMOTHERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SKIN DISEASE; UNSPECIFIED SIDE EFFECT; URINARY DYSFUNCTION; VASCULAR DISEASE;

EID: 33646387404     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2004-03-0930     Document Type: Article

References (34)

1. Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion. 2002;42:975-979.
2. Dodd R, Leiby D. Emerging infectious threats to the blood supply. Annu Rev Med. 2004;55:191-207.
3. Centers for Disease Control and Prevention (CDC). West Nile virus activity - United States, September 26-October 2, 2002, and investigations of West Nile virus infections in recipients of blood transfusion and organ transplantation. MMWR Morb Mortal Wkly Rep. 2002;51:884-895.
4. Alfonso R, Lin C, Dupuis K, et al. Inactivation of viruses with preservation of coagulation function in fresh frozen plasma [abstract]. Blood. 1996;88(suppl 1):526a.
5. de Alarcon P, Benjamin R, Dugdale M, et al. Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation (PCT-FFP): transfusion of patients with congenital factor deficiencies. Transfusion. 2005;45:1362-1372.
6. Hambleton J, Wages D, Radu-Radulescu L, et al. Pharmacokinetic study of FFP photochemically treated with amotosalen (S-59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin. Transfusion. 2002;42:1302-1307.
7. Wieding JU, Rathberger J, Zenjer D. Prospective, randomized trial and controlled study on solvent detergent versus methylene blue virus inactivated plasma [abstract]. Transfusion. 1999;39:23S.
8. Freeman JW, Williamson LM, Llewelyn C, et al. A randomized trial of solvent/detergent and standard fresh frozen plasma in the treatment of the coagulopathy seen during orthotopic liver transplantation. Vox Sang. 1998;74(suppl 1):225-229.
9. McCullough J, Vesole DH, Benjamin RJ, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT trial. Blood. 2004;104:1534-1541.
10. vanRhenen D, Gulliksson H, Cazenave JP, et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood. 2003;101:2426-2433.
11. Lin L, Conlan MG, Tessman J, Cimino G, Porter S. Amotosalen interactions with platelet and plasma components: absence of neoantigen formation after photochemical treatment. Transfusion. 2005;45:1610-1620.
12. Beeck H, Hellstern P. In vitro characterization of solvent/detergent- treated human plasma and quarantine fresh frozen plasma. Vox Sang. 1998;74(suppl 1):219-223.
13. Lee M, Morfini S, Schulman S, et al. The design and analysis of pharmacokinetic studies of coagulation factors. Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. 2001. http://www.med.unc.edu/isth/SSC/communications/factor8and9/fviiipharmaco.pdf. Accessed July 6, 2001.
14. Lerner RG, Nelson J, Scorcia G, et al. Evaluation of solvent/detergent- treated plasma in patients with prolonged prothrombin time. Vox Sanguinis. 2000;79:161-167.
15. Wages D, Smith D, Walsh J, et al. Transfusion of therapeutic doses of virally inactivated fresh frozen plasma in healthy subjects [abstract]. Blood. 1997;90(suppl 1):409a.
16. Nghiem HV, Tran K, Winger T. Imaging complications of liver transplantation. Radiographics. 1996;16:825-840.
17. Fiebig EW, Heldebrant CM, Smith RI, Conrad AJ, Delwart EL, Busch MP. Intermittent low-level viremia in very early primary HIV-1 infection. J Acquir Immune Defic Syndr. 2005;39:133-137.
18. Allain JP. Occult hepatitis B virus infection: implications in transfusion. Vox Sang. 2004;86:83-91.
19. Cyranoski D. Tainted transfusion leaves Japan scrambling for safer blood tests. Nat Med. 2004;10:217.
20. Harrington T, Kuehnert MJ, Kamel H, et al. West Nile virus infection transmitted by blood transfusion. Transfusion. 2003;43:1018-1022.
21. Horowitz B, Bonomo R, Prince AM, Chin SN, Brotman B, Shulman RW. Solvent/detergent treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood. 1992;79:826-831.
22. Garwood M, Cardigan RA, Drummond O, et al. The effect of methylene blue photoinactivation and methylene blue removal on the quality of fresh-frozen plasma. Transfusion. 2003;43:1238-1247.
23. Corten L, Wiesehahn G, Smyers J, Murthy KK, McClure HM, Alter H. Photochemical inactivation of hepatitis B (HBV) and hepatitis C (HCV) viruses in human plasma as assessed in a chimpanzee infectivity model [abstract]. Blood. 2000;96(suppl 1):253a-254a.
24. Dupuis K, Alfonso R, Savoor A, et al. Helinx technology used in the INTERCEPT Blood System inactivates emerging insect-borne pathogens in platelets and red cells. Blood Banking Transfusion Med, Proc VIII Eur Congress of ISBT. 2003;1(suppl 1):S292.
25. Williamson LM, Llewelyn CA, Fisher NC, et al. A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation. Transfusion. 1999;39:1227-1234.
26. Plasma. In: Goodnight SH, Hathaway WE, eds. Disorders of Hemostasis and Thrombosis: A Clinical Guide. 2nd ed. New York, NY: McGraw-Hill; 2001:495-500.
27. McCullough J. Transfusion therapy in specific clinical situations. In: McCullough J. Transfusion Medicine. New York, NY: McGraw-Hill; 1998:275-317.
28. Howdle PD. Clinical evaluation of the patient with liver disease. In: Howdle PD, ed. Comprehensive Clinical Hepatology. London, England: Harcourt; 2000:2.4.1-2.4.15.
29. Moore K. Hepatorenal syndrome and other renal diseases. In: Howdle PD, ed. Comprehensive Clinical Hepatology. London, England: Harcourt; 2000:2.8.1-2.8.16.
30. Flamholz R, Jeon HR, Baron JM, Baron BW. Study of three patients with thrombotic thrombocytopenic purpura exchanged with solvent/detergent-treated plasma: is its decreased protein S activity clinically related to their development of deep venous thrombosis? J Clin Apher. 2000;15:169-172.
31. Yarranton H, Cohen H, Pavord SR, Benjamin S, Hagger D, Machin SJ. Venous thromboembolism associated with management of acute thrombotic thrombocytopenic purpura. Br J Haematol. 2003;121:778-785.
32. Williamson LM, Cardigan R, Prowse CV. Methylene blue-treated fresh-frozen plasma: what is the contribution to blood safety? Transfusion. 2003;43:1322-1329.
33. Atance R, Pereira A, Ramirez B. Transfusing methylene blue-photoinactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate. Transfusion. 2001;41:1548-1552.
34. Mintz PD, Neff A, MacKenzie M, et al. Therapeutic plasma exchange (TPE) for thrombotic thrombocytopenic purpura (TTP) using plasma prepared with photochemical treatment (INTERCEPT Plasma) [abstract]. Blood. 2004;104:239a.